FivePrime Therapeutics, Inc. Provides an Update on Its Strategic Discovery Collaborations With Pfizer and GlaxoSmithKline

Published: Jun 16, 2011

SOUTH SAN FRANCISCO, California, June 16, 2011 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (FivePrime), a leader in the discovery and development of innovative biologics, announced today the completion of the three-year funded research program with Pfizer Inc. (NYSE:PFE), that began in 2008 and focused on the discovery of antibody targets and novel therapeutic protein products to treat multiple cancer indications and diabetes. During the three-year research program, FivePrime designed and conducted cell-based and primary in vivo screens against FivePrime's comprehensive library of extracellular proteins and successfully identified numerous targets that may lead to future protein or antibody candidates. FivePrime screened more than 1,000 extra-cellular domains of receptor proteins in vivo in animal models of disease as part of the research program. FivePrime also conducted target validation work and advanced studies of leads and targets identified in the research program.

Back to news